A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

@article{Sym2008API,
  title={A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer},
  author={Sun Jin Sym and Heung Moon Chang and Hye Jin Kang and Sung Sook Lee and Min-Hee Ryu and J S Lee and Taewon Kim and Jeong Hwan Yook and Sung Tae Oh and Byung Sik Kim and Yoon-koo Kang},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2008},
  volume={63},
  pages={1-8}
}
Irinotecan (I) and docetaxel (D), each of which has a unique mechanism of action, were recently introduced in the treatment of patients with advanced gastric cancer (AGC). We have evaluated the efficacy and safety of the ID combination for AGC patients after failure of fluoropyrimidine- or platinum-based chemotherapy. Patients with relapsed or progressive AGC after prior fluoropyrimidine- or platinum-based chemotherapy were treated with I (160 mg/m2, 90 min) followed by D (65 mg/m2, 1 h) every… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…